Agnholt J, Mikkelsen J H, i Bud M, Møller-Petersen J, Rasmussen S N, Dyerberg J
Dept. of Medical Gastroenterology, Aalborg Hospital, Denmark.
Scand J Gastroenterol. 1990 Jan;25(1):40-4. doi: 10.3109/00365529008999207.
The prognostic value of plasma prekallikrein activity, prothrombin time, and serum albumin with regard to survival in chronic liver insufficiency was evaluated in 21 consecutive patients. Twenty patients had liver cirrhosis, and one patient had malignant liver disease (hepatocellular carcinoma). Eight patients died between 4 and 43 days after the time of blood sampling. These patients had a prekallikrein value less than 0.42. There were no overlapping prekallikrein values between patients who died and patients who survived (overlap index 0; p less than 0.001). Overlap index for prothrombin time was 0.35 (p less than 0.02), and for serum albumin 0.34 (p less than 0.02). In conclusion, plasma prekallikrein seems to indicate whether death is imminent in patients with liver insufficiency due to cirrhosis. Longitudinal studies of prekallikrein activity in different subgroups of patients with chronic and acute liver disease are recommended.
对21例连续的慢性肝功能不全患者评估了血浆前激肽释放酶活性、凝血酶原时间和血清白蛋白对生存的预后价值。20例患者患有肝硬化，1例患者患有肝脏恶性疾病（肝细胞癌）。8例患者在采血后4至43天内死亡。这些患者的前激肽释放酶值低于0.42。死亡患者和存活患者之间的前激肽释放酶值没有重叠（重叠指数为0；p小于0.001）。凝血酶原时间的重叠指数为0.35（p小于0.02），血清白蛋白的重叠指数为0.34（p小于0.02）。总之，血浆前激肽释放酶似乎可以表明肝硬化所致肝功能不全患者是否即将死亡。建议对慢性和急性肝病不同亚组患者的前激肽释放酶活性进行纵向研究。
